Keros Therapeutics (KROS) shares were down 72% pre-bell Thursday after the company said it voluntarily halted two treatment arms in a phase 2 study of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension.
Samfine Creation (SFHG) stock was 36% lower, extending Wednesday's fall.
Intellinetics (INLX) shares were down 21% following a muted session.
Chatham Lodging Trust (CLDT) stock was 19% lower after closing nearly unchanged on Wednesday.
Myriad Genetics (MYGN) shares were down 17%, adding to Wednesday's losses.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。